Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by floatinketuckyon Feb 03, 2022 9:13am
537 Views
Post# 34392507

70 percet and less dossed patients.

70 percet and less dossed patients.
$TLTFF I'm expecting the number to come up slowly. The first dozen patients treated on the first round at a low dose. Now the full-strength data is coming in and the 70% dozen patients are of course in the numbers too. I'm expecting it to increase modestly as the study is now starting to show full strength data.
 
67% CR in Phase one study at 18 months on one full dose treatment. Patients were released from the study at 18 months. But the doctor knows his patient and only they know the 24 mo. results.
 
But Principal Investigator After all that set the first 12 patients in the phase 2 PIVATOL at about 70 percent dose. I think he had in mind not to over treat AND to mop up the second treatment at full dose.

<< Previous
Bullboard Posts
Next >>